David Smadja/Wikipedia
Jun 7, 2025, 08:46
David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
David Smadja, Team Director “Endotheliopathy and hemostasis disorders” at INSERM The Paris Cardiovascular Research Center, shared a post on LinkedIn:
“A major step forward in the fight against cancer-related thrombosis!
In the journal VAINCRE LE CANCER – NRB, we take a look back at the API-CAT study, led by Prof. Isabelle Mahé (Louis Mourier Hospital AP-HP) and our team at PARCC – Inserm Endotheliopathy & Hemostasis Disorders.
Result? A reduced dose of apixaban is sufficient to prevent thromboembolic recurrence with less bleeding.
This is further proof that academic research is changing clinical practices. Proud to contribute to this breakthrough in the service of cancer patients.”
You can read a wide variety of new scientific posts in Hemostasis Today.
-
Aug 25, 2026, 00:07Muhammad Ali Khan: Using EHR Data to Predict Fibrotic Progression in PV and ET
-
Aug 25, 2026, 00:06Michael R. Scoma: The Vascular Dimension of Long COVID
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada